Leadership Team
Meet the passionate and experienced minds driving innovation at 92Bio.
Board Of Directors
Jeff Bird, MD, PhD
Jeff Bird is Managing Director of Bluebird Ventures. He is also a Partner at Sutter Hill Ventures where he has been an investor for 21 years and where he led investments in biotechnology and genomics. Jeff was a Series A investor in Forty Seven, Portola, Teneobio, Helix and Grail. He served as CEO of Verinata Health, a genomic diagnostic company sold to Illumina, where he served as GM for one year. Jeff was formerly an executive at Gilead Sciences for over ten years. He received his undergraduate degree as well as an MD and PhD in Cancer Biology from Stanford.
Olivia Bloom
In September 2023, after a 29-year career with Geron Corporation, a publicly traded clinical stage biopharmaceutical company, Ms. Bloom retired as Executive Vice President, Chief Financial Officer and Treasurer. During that tenure, Ms. Bloom held several financial management positions, including Chief Accounting Officer and Controller, as well as lead several operational functions, including purchasing, information technology and investor relations. Ms. Bloom started her career in public accounting at KPMG International Limited and became a Certified Public Accountant in 1994. Ms. Bloom holds a B.S. in Business Administration from the University of California, Berkeley and is a Phi Beta Kappa.
Jonathan MacQuitty, PhD
Jonathan joined Lightspeed in 2016 with over three decades of operating and investing experience in healthcare and life sciences. Since then, Jonathan has been instrumental in life science investing for Lightspeed, leading investments in Forty Seven (acquired by Gilead for $4.9B), Orca Bio, and Teneobio (acquired by Amgen for up to $2.5B). Prior to Lightspeed, Jonathan served as a partner and head of the West Coast office of Abingworth, a UK based venture capital firm focused on life sciences. He was also CEO of GenPharm International, a Bay Area biotech company developing a novel human sequence antibody platform. Jonathan holds a PhD in Chemistry from the University of Sussex, an MBA from Stanford Graduate School of Business, and a BA and MA in Chemistry from Oxford University.
Galym Imanbayev, MD, MBA
Galym joined Lightspeed in 2020 as a Partner focused on the Health sector. He is a board member of 92Bio, Fathom, Frontera Health, Soda Health, and Wheel, and is a board observer of Abridge and Aledade. Previously, Galym was an investor at Capricorn Healthcare & Special Opportunities (Martis Capital) and spent time with Data Collective VC, Healthtech Capital, and Pear VC. Additionally, Galym was consulting faculty for Stanford Medicine X and served as the graduate representative on the Stanford University Board of Trustees. Outside of investment and strategy roles, Galym performed research in a number of labs, publishing peer-reviewed papers in gene therapy, stem cell biology, and medical imaging. Galym received his BA, MD, & MBA from Stanford University.
Michael Bigham, MBA
Michael has over 35 years of leadership experience in the biopharmaceutical industry. Mr. Bigham is a Founder and Managing General Partner of Firebrand River Capital LLC. From 2019 to 2023, he served as the Executive Chairman of Paratek Pharmaceuticals where he also served as the CEO from 2014 to 2019. From 2003 to 2015, he was a general partner at Abingworth LLP. Mr. Bigham has served on the boards of numerous life sciences companies including the Frazier Life Sciences Acquisition Corporation, Avila Therapeutics, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro, Adamas Pharmaceuticals and Magellan Biosciences. He was formerly Vice Chairman of Corixa Corporation, and was President and CEO of Coulter Pharmaceuticals until it merged into Corixa. He was an early employee at Gilead Sciences where he served as Executive VP of Operations and CFO. Before joining Gilead Sciences, Mr. Bigham was a Partner at Hambrecht & Quist. He currently serves on the boards of several private life sciences companies. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.
Jill Carroll
Jill is a Partner with SR One based on the East Coast. Jill’s educational background is in biochemistry and her career has spanned 20 years in various facets of the biotechnology industry. Initially, she spent time in strategy consulting focusing on commercial projects with pharma, then migrated to operating roles in corporate development, particularly at Dynavax Technologies (DVAX), where she completed multiple pharma partnerships and private and public financings. Jill started her investing career at SR One in 2011 and has been involved in marquee investments including Alios Biopharma, Progyny (PGNY) and Principia Biopharma (PRNB), among others. Jill received a BS in chemistry from Duke University and a MS in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.
Ben Buelow, MD, PhD
Dr. Ben Buelow is the CEO and one of the founding team members at 92Bio. Previously he served as CEO of Ancora Biotech from 2022 to 2024 and Chief Medical Officer of Teneobio, Inc. from 2016 to 2021, when it was acquired by Amgen. Ben completed his residency and surgical pathology fellowship as chief resident at UCSF in 2016. He received an MD with honors and a PhD in Immunology from the University of Washington in 2011. Ben is the author of ~25 peer reviewed publications and has presented at numerous national and international scientific meetings.
